ACR CONVERGENCE 2020—New evidence, though derived from small numbers, suggest that treatment with the TNF-inhibitor certolizumab could help improve high-risk pregnancy outcomes in women with antiphospholipid syndrome (with or without systemic lupus erythematosus) and lupus anticoagulants, an expert said. In the Phase 2 IMPACT trial, which has already enrolled 27 women and is continuing to…
Racial Disparities in Rheumatology: RA, OA & Arthroplasty
ACR CONVERGENCE 2020—Evidence shows that African Americans have a higher burden of osteoarthritis, with lower use of conventional medications, and are less adherent to the medications they take. They also get arthroplasty procedures less often, and when they do have the procedures, they report greater pain, worse function and lower satisfaction with them. In RA…
FAST Results for Febuxostat Safety in Patients with Gout
ACR CONVERGENCE 2020—The results of a post-authorization study comparing the cardiovascular safety of febuxostat vs. allopurinol were presented in a late-breaking abstract session at the ACR’s fully virtual annual meeting on Monday, Nov. 9. Cardiologist Thomas MacDonald, MD, FRCP, MBChB, clinical professor (teaching and research) of molecular and clinical medicine, University of Dundee School of…
Lupus Immunology Trends Provide Insights for Rheumatologists
ACR CONVERGENCE 2020—With an understanding of the key causes that are behind immune abnormalities in systemic lupus erythematosus (SLE), rheumatologists gain insights into this disease. During the ACR Convergence session Immunology Update—The Decade in Review: 10 Steps to SLE, Chandra Mohan, MD, PhD, Hugh Roy and Lillie Cranz Cullen Endowed Professor, University of Houston, provided…
RA Patients with ILD & Liver Disease Present Treatment Challenges
ACR CONVERGENCE 2020—Patients with concurrent rheumatological arthritis (RA) and liver disease or interstitial lung disease or treatment-refractory rheumatoid arthritis pose treatment challenges, according to the panelists of the ACR Convergence 2020’s How I Treat Difficult RA: Panel Session. Each panelist discussed a difficult case and raised questions on how to best treat it. Joan M….
Newer Targets Pave the Way for Future Lupus Therapies
ACR CONVERGENCE 2020—Although rheumatologists have struggled with a lack of new therapies for systemic lupus erythematosus (SLE), recent positive trial results have brought renewed hope for more treatments. That was the theme of the ACR Convergence 2020 session, State of the Art: Lupus—The Future Is Now, led by Peggy Crow, MD, the Benjamin M. Cohen…
The New Guidance Subcommittee Gives ACR More Document Flexibility
The ACR publishes multiple types of documents to provide guidance for its members, but some potentially beneficial topics have not fit neatly into existing production pathways. To answer the need, the ACR has formed a Guidance Subcommittee to the Quality of Care (QOC) Committee. This will allow the ACR to adapt more nimbly, when appropriate,…
View On-Demand Sessions & Content from ACR Convergence 2020
Content from ACR Convergence 2020, including scientific sessions, posters, exhibits, and community hubs, is available to All-Access Pass and COVID-19 Pass participants to view and access on-demand through March 11, 2021. View sessions you missed and related Q&As with the speakers, read and catch up on posters, interact with exhibits and industry events, and view…
How to Terminate a Patient Relationship
The success of a physician-patient relationship encompasses several important factors, including mutual respect, trust and effective communication. But what can be done when this relationship becomes adversarial and communication breaks down? The American Medical Association has historically pointed out that poor physician-patient communication is directly related to malpractice or discrimination lawsuits. When providers end a…
Study: DPP4 Inhibitors Yield Promise for Systemic Sclerosis Treatment
A recent paper in Arthritis & Rheumatology opens up the possibility of a new research avenue to treat systemic sclerosis: dipeptidyl peptidase 4 (DPP4) inhibitors, a previously approved therapy for type 2 diabetes.1 Work in mouse models and on skin samples from systemic sclerosis patients suggests these drugs pose a promising area of future translational…
- « Previous Page
- 1
- …
- 71
- 72
- 73
- 74
- 75
- …
- 304
- Next Page »